FIGO分期系统对原发性女性生殖道淋巴瘤的预后准确性更高:一项回顾性研究(IELSG35)

IF 3.3 4区 医学 Q2 HEMATOLOGY
Maria Cristina Pirosa, Sara Steffanoni, Anna Vanazzi, Fabiana Esposito, Angela Polino, Alberto Schena, Francesco Landi, Maria Elena Cabrera, Saad Akhtar, Santiago Gardella, Osnat Bairey, Astrid Pavlovsky, Anastasios Stathis, Emanuele Zucca
{"title":"FIGO分期系统对原发性女性生殖道淋巴瘤的预后准确性更高:一项回顾性研究(IELSG35)","authors":"Maria Cristina Pirosa,&nbsp;Sara Steffanoni,&nbsp;Anna Vanazzi,&nbsp;Fabiana Esposito,&nbsp;Angela Polino,&nbsp;Alberto Schena,&nbsp;Francesco Landi,&nbsp;Maria Elena Cabrera,&nbsp;Saad Akhtar,&nbsp;Santiago Gardella,&nbsp;Osnat Bairey,&nbsp;Astrid Pavlovsky,&nbsp;Anastasios Stathis,&nbsp;Emanuele Zucca","doi":"10.1002/hon.3312","DOIUrl":null,"url":null,"abstract":"<p>Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (<i>n</i> = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, <i>n</i> = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3312","citationCount":"0","resultStr":"{\"title\":\"Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)\",\"authors\":\"Maria Cristina Pirosa,&nbsp;Sara Steffanoni,&nbsp;Anna Vanazzi,&nbsp;Fabiana Esposito,&nbsp;Angela Polino,&nbsp;Alberto Schena,&nbsp;Francesco Landi,&nbsp;Maria Elena Cabrera,&nbsp;Saad Akhtar,&nbsp;Santiago Gardella,&nbsp;Osnat Bairey,&nbsp;Astrid Pavlovsky,&nbsp;Anastasios Stathis,&nbsp;Emanuele Zucca\",\"doi\":\"10.1002/hon.3312\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (<i>n</i> = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, <i>n</i> = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3312\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.3312\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3312","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

女性生殖道原发性淋巴瘤(PLFGT)是一种罕见的结外淋巴瘤。在这项由国际结节外淋巴瘤研究小组(International Extranodal Lymphoma Study Group)开展的回顾性研究中,我们分析了在1982年至2012年间确诊为PLFGT的60名女性患者的临床数据。中位年龄为 52 岁。根据安娜堡和 FIGO 分期系统的定义,分别有 55% 和 63% 的病例处于局限期。子宫是25例淋巴瘤患者的主要发病部位,卵巢是第二常见的发病部位(24例)。最常见的组织学亚型是弥漫大B细胞淋巴瘤(DLBCL,44例),其次是滤泡淋巴瘤和边缘区淋巴瘤(各6例)。2名患者接受了单纯手术作为一线治疗,58名患者接受了全身治疗,其中16名患者在接受大手术后接受了全身治疗。13名患者接受了巩固放疗,6名患者接受了中枢神经系统(CNS)预防治疗。20名患者出现了疾病进展或复发。6名DLBCL患者(14%)出现中枢神经系统复发,其中5人的复发部位只有中枢神经系统。除一名中枢神经系统复发患者外,其他所有患者均有原发性卵巢受累,其中三名患者的疾病体积较大;这些患者均未接受中枢神经系统预防治疗。中位随访时间为60个月,DLBCL队列的中位总生存期约为13年,5年生存率为77%。在多变量分析中,根据FIGO系统划分的晚期疾病是唯一与DLBCL患者较短的总生存期、病因特异性生存期和无进展生存期显著相关的参数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)

Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (n = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, n = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信